NVNO enVVeno Medical
- 5.180
- -0.050-0.96%
enVVeno Medical News
Positive 11 Month Topline Efficacy Data Showing Significant Clinical Improvement From EnVVeno Medical's VenoValve(R) Pivotal Trial to Be Presented Today at the 46th Annual Charing Cross Symposium
Overall 8.46 Average Revised Venous Clinical Severity Score (rVCSS) Improvement Per Patient for Patients Showing Clinical Meaningful Benefit (rVCSS Improvement ≥ 3 Points) including:9.29 Points for Pa
Express News | New Topline Efficacy Data From EnVVeno Medical VenoValve Pivotal Trial To Be Presented At 46th Annual Charing Cross Symposium On April 24, 2024
New Topline Efficacy Data From the EnVVeno Medical VenoValve(R) Pivotal Trial to Be Presented at the 46th Annual Charing Cross Symposium on April 24, 2024
IRVINE, CA / ACCESSWIRE / April 16, 2024 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today an
EnVVeno Medical Appoints Andrew Cormack as Its Chief Commercial Officer
Appointment bolsters Company's transition from being a clinical stage to a commercial entity planning for the monetization of the VenoValvePMA application seeking FDA approval for the VenoValve on track to be filed
EnVVeno Medical(NVNO.US) Officer Sells US$51,837.48 in Common Stocks
$enVVeno Medical(NVNO.US)$ Officer Alavi Hamed sold 8,334 shares of Common Stocks on Mar 13, 2024 at an average price of $6.22 for a total value of $51,837.48.Source: Announcement What is statement of
EnVVeno Medical to Participate in the Virtual Investor Lunch Break: The EnVVeno Opportunity
Live video webcast with Robert Berman, Chief Executive Officer of enVVeno Medical on Thursday, March 21st at 12:00 PM ETIRVINE, CA / ACCESSWIRE / March 15, 2024 / enVVeno Medical Corporation
EnVVeno Announces Positive Topline Efficacy Data for VenoValve US Pivotal Trial
EnVVeno Medical (NVNO) announced "positive topline efficacy data showing significant clinical improvement" from the US pivotal trial for VenoValve, a surgical replacement being developed for severe ch
BeyondSpring, EnVVeno Medical, Aptorum Group Among Healthcare Movers
EnVVeno Medical's VenoValve Trial Shows Promising Results
Positive Topline Efficacy Data Showing Significant Clinical Improvement From EnVVeno Medical's VenoValve(R) Pivotal Trial to Be Presented Today at the VENOUS2024 American Venous Forum Annual Meeting
97% of VenoValve Study Patients Showing Clinical Improvement at Six Months (as Measured by the Revised Venous Clinical Severity Score (rVCSS))74% of the Study Patients Showing Clinical Meaningful Bene
Companies Like EnVVeno Medical (NASDAQ:NVNO) Are In A Position To Invest In Growth
EnVVeno Medical Reports FY Results
Recap: EnVVeno Medical Q4 Earnings
enVVeno Medical (NASDAQ:NVNO) reported its Q4 earnings results on Thursday, February 29, 2024 at 04:15 PM.Here's what investors need to know about the announcement.EarningsenVVeno Medical beat estimat
Express News | EnVVeno Medical Q4 EPS $(0.32) Beats $(0.46) Estimate
EnVVeno Medical Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
$46.4 million cash and investments on hand sufficient to fund current operations, including multiple value driving milestones, through the end of 2025Topline efficacy data for VenoValve U.S. pivotal t
Express News | EnVVeno Medical To Present Topline Efficacy Data From VenoValve Trial At The 2024 American Venous Forum Annual Meeting Mar. 6
Topline Efficacy Data From the EnVVeno Medical VenoValve(R) Pivotal Trial to Be Presented at the VENOUS2024 American Venous Forum Annual Meeting on March 6, 2024
IRVINE, CA / ACCESSWIRE / February 20, 2024 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today
EnVVeno Medical Corporation's (NASDAQ:NVNO) Path To Profitability
EnVVeno Medical Posts Company Highlights and Materials From 2023 VEITH Symposium
- Interviews with patients from the VenoValve pivotal study- Materials now available on the Company's websiteIRVINE, CA / ACCESSWIRE / December 14, 2023 / enVVeno Medical Corporation (NASDAQ:NVNO) ("e
EnVVeno Medical Presents Positive Preliminary Device Related Material Adverse Event (MAE) Data From the VenoValve Pivotal Trial at the 50th Annual VEITH Symposium
No Deaths or Pulmonary Embolisms Occurring During the 30 Day MAE PeriodExpected Overall Device-Related Material Adverse Event Rate of 8% for the Fully Enrolled 75 Patient StudySix (6) DVT Related MAEs
Analysis
Price Target
No Data
